Grand Pharmaceutical H1 revenue rises on nuclear medicine demand

Grand Pharmaceutical

26/08/2026 14:54

Overview
Hong Kong-listed pharma group's H1 revenue rose 3.2% yr/yr to HK$6.39 bln
Net income attributable to owners fell to HK$1.06 bln from HK$1.19 bln last year
Nuclear medicine segment revenue rose 55% on higher demand and new product sales

Outlook
Company expects robust pipeline to drive long-term growth, with R&D milestones in 2027-2028

Result Drivers
NUCLEAR MEDICINE DEMAND - Co said nuclear medicine segment revenue rose 55% on rapid rise in clinical demand and scaling up sales volumes for new products
AMINO-ACID PRICING – Biotechnology revenue rose 34.2%, driven by higher core-product prices and expanding downstream demand

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
HK$6.39 bln
 
H1 Net Income Attributable
 
HK$1.06 bln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 12 three months ago

Reuters Recommended Reads
Aug 26 - China's Hansoh Pharma posts 36% rise in first-half profit helped by innovative drug sales
Aug 26 - Sihuan Pharmaceutical H1 profit jumps on medical aesthetics unit strength
Aug 26 - China's Jiangsu says it will support pharmaceutical firms' global M&A, licensing

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)